While all ACE inhibitors are believed equally effective only three beta blockers have proven effectiveness in patients with left ventricular systolic dysfunction.  Beta blockers are remarkably different in their effects and the three guideline directed agents are also quite different. They are each very different and understanding these differences through clinical trials (bisoprolol, carvedilol, or sustained-release metoprolol succinate) are recommended for all hemodynamically stable patients without documented contraindications (Class I, Level A). It is particularly important to titrate these agents slowly into the “green zone” where the risk benefit ratio supports use of these agents.